News >

PET-Adapted Therapy Effective in Hodgkin Lymphoma

Jason Harris
Published: Friday, Jan 26, 2018

 Alessandro Rambaldi, MD

Alessandro Rambaldi, MD
Investigators successfully used PET/CT scanning to determine whether patients with stage IIB to IVB Hodgkin lymphoma should switch from ABVD to BEACOPP, according to updated results from the international GITIL/FIL HD 0607 trial published in the Journal of Clinical Oncology.

In previous studies, ABVD (doxorubicin, vinblastine, vincristine, and dacarbazine) has been associated with a 3- to 5-year progression-free survival (PFS) ranging from 61% to 76%. The more intensive BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has shown superior disease control, with a 5-year freedom from treatment failure of up to 90%, but at the cost of increased toxicity. BEACOPP has been associated with increased hematologic toxicity, a high incidence of sterility, and severe late complications/long-term toxicities including a 5-year cumulative risk for myelodysplastic syndrome or acute leukemia of 2.2% compared with 0.4% for ABVD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x